← ANALYST RATINGS · TIPRANKS

Alkermes (ALKS): analyst forecast and price target

$41.22 +2.79% close 16.10.26 · market cap $6.7B · Healthcare · Drug Manufacturers - Specialty & Generic IWM 0.23%
Price targets and ratings of

Analyst consensus

Moderate Buy

7 Buy2 Hold1 Sell

Ratings of 10 analysts in the last 3 months · top analysts only

12-month forecast

$59.22+43.7% upside

Based on 10 price targets given in the last 3 months, the average target is $59.22, the highest $83.00, the lowest $38.00. The average is +43.7% from the last price of $41.22.

$40.00$60.00$80.00Jan 26AprJulOctJan 27AprJulOctHigh$83.00Average$59.22Low$38.00
Highest target $83.00 Average target $59.22 Lowest target $38.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% Bank of America Securities $38.00 Sell −7.8% Reiterated 09.10.26on TipRanks 08:55 +0.6%next day −0.8% · 5 days +3.5%
Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% RBC Capital $56.00 Buy +35.9% Reiterated 08.10.26on TipRanks 21:45 +0.6%next day −0.8% · 5 days +3.5%
Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% Stifel Nicolaus $63.00 Buy +52.8% Reiterated 05.10.26on TipRanks 06:55 +1.7%next day −3.1% · 5 days −6.3%
Andrea Newkirk★★★★★★★★★★#2841 · hits 50% · avg +29.4% Goldman Sachs $50.00 Hold +21.3% Initiated 24.09.26on TipRanks 07:40 −3.1%next day −0.4% · 5 days −0.2%
Akash Tewari★★★★★★★★★★#649 · hits 57% · avg +13.5% Jefferies $78.00 → $83.00+6.4% Buy +101.4% Reiterated 22.09.26on TipRanks 08:55 −2.0%next day −2.0% · 5 days −4.6%
Luke Herrmann Robert W. Baird $58.00 → $61.00+5.2% Buy +48.0% Reiterated 22.09.26on TipRanks 07:25 −2.0%next day −2.0% · 5 days −4.6%
Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% Mizuho Securities $65.00 Buy +57.7% Reiterated 22.09.26on TipRanks 06:50 −2.0%next day −2.0% · 5 days −4.6%
Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% J.P. Morgan — Hold — Reiterated 21.09.26on TipRanks Sep 22 07:35 +0.3%next day −2.0% · 5 days −8.1%
Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% H.C. Wainwright $43.00 Hold +4.3% Reiterated 21.09.26on TipRanks 12:45 +0.3%next day −2.0% · 5 days −8.1%
Ami Fadia★★★★★★★★★★#73 · hits 59% · avg +36.1% Needham $62.00 Buy +50.4% Reiterated 21.09.26on TipRanks 10:15 +0.3%next day −2.0% · 5 days −8.1%
David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% Piper Sandler $65.00 Buy +57.7% Reiterated 06.08.26on TipRanks 07:01 −2.3%next day +1.0% · 5 days +1.0%
Benjamin Burnett★★★★★★★★★★#5339 · hits 45% · avg +1.7% Wells Fargo $65.00 Buy +57.7% Assigned 29.07.26on TipRanks 07:02 −2.7%next day +1.8% · 5 days −2.9%
Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% TD Cowen $57.00 → $58.00+1.8% Buy +40.7% Reiterated 28.07.26on TipRanks 13:30 −4.5%next day −2.7% · 5 days −5.8%
Ashwani Verma★★★★★★★★★★#1305 · hits 60% · avg +13.4% UBS $42.00 → $48.00+14.3% Buy +16.4% Reiterated 06.05.26on TipRanks 06:40 −4.0%next day +0.5% · 5 days +9.0%
Marc Goodman★★★★★★★★★★#365 · hits 56% · avg +19.2% Leerink Partners — Hold — Reiterated 31.03.26on TipRanks 13:25 +14.4%next day −1.6% · 5 days −5.6%
Pete Stavropoulos★★★★★★★★★★#2065 · hits 45% · avg +16.4% Cantor Fitzgerald $43.00 Buy +4.3% Reiterated 11.03.26on TipRanks Mar 12 08:25 +0.2%next day +1.1% · 5 days +0.2%
Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% Truist Financial — Buy — Reiterated 26.02.26on TipRanks Feb 27 02:35 −0.4%next day −1.6% · 5 days −6.6%
Rudy Li★★★★★★★★★★#235 · hits 63% · avg +76.1% Wolfe Research $45.00 Buy +9.2% Initiated 23.02.26on TipRanks Feb 24 03:35 +1.9%next day +3.0% · 5 days −6.6%
David Hoang★★★★★★★★★★#485 · hits 67% · avg +34.8% Deutsche Bank $55.00 → $45.00−18.2% Buy +9.2% Reiterated 13.11.25on TipRanks 04:15 +0.4%next day −6.3% · 5 days −6.2%
Umer Raffat★★★★★★★★★★#2336 · hits 50% · avg +9.4% Evercore ISI — Buy — Reiterated 12.11.25on TipRanks 12:55 −7.2%next day +0.4% · 5 days −5.6%
Unknown Analyst Roth MKM $50.00 Buy +21.3% Initiated 10.11.25on TipRanks Nov 11 12:10 −2.3%next day +3.3% · 5 days −7.9%

The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included

Best analysts covering Alkermes

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Ami Fadia★★★★★★★★★★Needham · #73
Hits 59%297 of 500 Average return +36.1%
1 year Paul Matteis★★★★★★★★★★Stifel Nicolaus · #473
Hits 53%259 of 492 Average return +17.6%
2 years Joseph Thome★★★★★★★★★★TD Cowen · #320
Hits 57%201 of 352 Average return +24.8%

Most profitable

3 months Ami Fadia★★★★★★★★★★Needham · #73
Hits 59%297 of 500 Average return +36.1%
1 year Paul Matteis★★★★★★★★★★Stifel Nicolaus · #473
Hits 53%259 of 492 Average return +17.6%
2 years Joseph Thome★★★★★★★★★★TD Cowen · #320
Hits 57%201 of 352 Average return +24.8%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $59.08 at a price of $40.52 (+45.8%); now: $59.08 at $41.22 (+43.3%).

$40.00$50.00$60.00Sep 15Oct 1Oct 15Top analysts$59.22Average target$59.08Price$41.22

PriceAverage targetTop analysts’ target

Recommendation trend · top analysts

0204031512Oct 2571816Nov71311Dec695Jan 263114Feb4124Mar4155Apr3174May12541Jun3283Jul2463Aug31873Sep3722Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy310033
Buy17253224187
Hold448672
Sell013332

Earnings and sales forecast

Next report: 28.10.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $-0.08 (from $-0.15 to $0.00). Last quarter: $0.00.

Sales

Next quarter’s sales estimate — $464M (from $445M to $482M). Last quarter: $496M.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About Alkermes
  • CEO: Blair Jackson
  • Employees: 2,050
  • Connaught House, Dublin, DU, D04 C5Y6, IE
  • www.alkermes.com

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Data from the stock’s TipRanks forecast page, read 47 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗